Brief: Algernon Pharmaceuticals Files For Orphan Designation With FDA For Ifenprodil
19/09/2022 12:15
Sept 19 (Reuters) - Algernon Pharmaceuticals Inc AGN.CD :
* ALGERNON PHARMACEUTICALS FILES FOR ORPHAN DESIGNATION WITH
THE
U.S. FDA FOR IFENPRODIL AS A TREATMENT OF IPF
Source text for Eikon: ID:nGNX5Kn6f7
Further company coverage: AGN.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grey Matters Health
See all newsBrief: Grey Matters Announces The Closing Of Its Equity And Convertible Debenture Private Placement Totalling CAD $1.12 Million
Brief: Algernon Announces Additional Increase To Private Placement Financing
Brief: Algernon Health Announces Private Placement
Brief: Algernon Announces Closing Of The Private Placement Financing
Brief: Algernon Announces $1 Mln Private Placement